# SLC6A1

## Overview
The SLC6A1 gene encodes the solute carrier family 6 member 1 protein, commonly known as the gamma-aminobutyric acid (GABA) transporter 1 (GAT1). This protein is a transmembrane transporter integral to the plasma membrane, playing a crucial role in the reuptake of GABA, the primary inhibitory neurotransmitter in the central nervous system (CNS) (Pramod2013SLC6). GAT1 is predominantly expressed in neurons and is essential for maintaining GABA homeostasis and the excitatory/inhibitory balance necessary for normal brain function (Bhatt2024Unveiling). The protein operates by cotransporting sodium and chloride ions along with GABA, facilitating its rapid removal from the synaptic cleft and preventing excessive neuronal firing (Goodspeed2020Current). Mutations in the SLC6A1 gene are associated with various neurodevelopmental disorders, including epilepsy and intellectual disabilities, highlighting its clinical significance (Carvill2015Mutations).

## Structure
The SLC6A1 gene encodes the GABA transporter 1 (GAT1), a member of the solute carrier family 6. This protein is integral to the plasma membrane and is involved in the reuptake of gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the central nervous system (Pramod2013SLC6).

The primary structure of SLC6A1 consists of amino acid sequences that form the protein, which includes 12 transmembrane domains typical of the SLC6 family (Pramod2013SLC6). These transmembrane domains are crucial for the protein's function as they facilitate the transport of GABA across the cell membrane.

The secondary structure of SLC6A1 is characterized by alpha helices that span the membrane, forming a helical bundle. The tertiary structure involves the 3D folding of these helices, creating a substrate binding site and allowing for the coupling of sodium ions necessary for GABA transport (Rudnick2013The).

The quaternary structure of SLC6A1 may involve interactions with other proteins or subunits, although specific details are not provided in the context. Post-translational modifications, such as phosphorylation, can regulate the activity and localization of the transporter (Pramod2013SLC6). Splice variant isoforms of SLC6A1 may exist, potentially affecting its function and localization (Pramod2013SLC6).

## Function
The SLC6A1 gene encodes the gamma-aminobutyric acid (GABA) transporter 1 (GAT1), which is crucial for the reuptake of GABA, the primary inhibitory neurotransmitter in the central nervous system (CNS). GAT1 is predominantly expressed in neurons, particularly in the adult frontal cortex, and is responsible for the reuptake of approximately 80% of GABA from the synaptic cleft into presynaptic neurons (Goodspeed2020Current; Bhatt2024Unveiling). This reuptake is essential for maintaining GABA homeostasis and the excitatory/inhibitory (E/I) balance, which is vital for normal brain function and protection against excitotoxicity (Bhatt2024Unveiling).

GAT1 operates by cotransporting two sodium ions, one chloride ion, and one GABA molecule across the cell membrane, generating a stoichiometric current that facilitates the rapid removal of GABA from the synaptic cleft (Hirunsatit2009Twentyonebasepair; Goodspeed2020Current). This process prevents GABA from activating neighboring synapses, thus maintaining synaptic transmission and preventing excessive neuronal firing (Mattison2018SLC6A1variants). GAT1 is also involved in the transport of betaine, an endogenous osmolyte, which can modulate GABA uptake and contribute to maintaining the E/I balance in the CNS (Bhatt2024Unveiling).

## Clinical Significance
Mutations in the SLC6A1 gene, which encodes the GABA transporter 1 (GAT-1), are associated with a range of neurodevelopmental disorders. These include epilepsy syndromes such as myoclonic-atonic epilepsy (MAE), also known as Doose syndrome, characterized by myoclonic-atonic seizures and developmental delays (Carvill2015Mutations; Goodspeed2020Current). SLC6A1 mutations are also linked to intellectual disability, autism spectrum disorder (ASD), and attention deficit hyperactivity disorder (ADHD) (Kalvakuntla2023Patterns; Johannesen2023The). 

The gene's variants often result in a loss of GAT-1 function, leading to impaired GABA reuptake and altered neurotransmission, which can contribute to the development of these disorders (Trivisano2023Insights; Silva2022Haploinsufficiency). Clinical features commonly observed in individuals with SLC6A1 mutations include developmental delay, cognitive impairment, and various types of seizures, such as absence, myoclonic, and atonic seizures (Johannesen2018Defining; Fischer2022Molecular). 

In some cases, SLC6A1 mutations have been associated with psychiatric conditions like schizophrenia, although these cases typically do not involve epilepsy or intellectual disability (Goodspeed2020Current). The phenotypic spectrum of SLC6A1-related disorders is broad, with some individuals experiencing developmental regression and behavioral issues (Johannesen2018Defining; Kalvakuntla2023Patterns).

## Interactions
The SLC6A1 gene encodes the GABA transporter 1 (GAT1), which is involved in the reuptake of the neurotransmitter GABA in the central nervous system. GAT1 interacts with various proteins and ions to perform its function. It couples the translocation of GABA with the movement of sodium and chloride ions across the membrane, generating a stoichiometric current that prevents GABA from activating neighboring synapses (Goodspeed2020Current). This process is essential for maintaining the balance of neuronal excitation and inhibition.

GAT1 also functions as an ion channel, generating inward sodium currents and leak currents mediated by alkali ions (Goodspeed2020Current). The transporter is primarily expressed in GABAergic axon terminals but can also be found in astrocytes, oligodendrocytes, and microglia, indicating its involvement in a wide range of cellular interactions within the central nervous system (Goodspeed2020Current).

Mutations in the SLC6A1 gene, such as the G234S variation, can impair the trafficking and function of the GAT1 protein, leading to reduced cell surface expression and GABA uptake. This highlights the importance of proper protein interactions for the stability and function of GAT1 (Cai2019A).


## References


[1. (Trivisano2023Insights) Marina Trivisano, Ambra Butera, Chiara Quintavalle, Angela De Dominicis, Costanza Calabrese, Simona Cappelletti, Federico Vigevano, Antonio Novelli, and Nicola Specchio. Insights into cognitive and behavioral comorbidities of slc6a1-related epilepsy: five new cases and literature review. Frontiers in Neuroscience, August 2023. URL: http://dx.doi.org/10.3389/fnins.2023.1215684, doi:10.3389/fnins.2023.1215684. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fnins.2023.1215684)

[2. (Johannesen2018Defining) Katrine M. Johannesen, Elena Gardella, Tarja Linnankivi, Carolina Courage, Anne de Saint Martin, Anna‐Elina Lehesjoki, Cyril Mignot, Alexandra Afenjar, Gaetan Lesca, Marie‐Thérèse Abi‐Warde, Jamel Chelly, Amélie Piton, J. Lawrence Merritt, Lance H. Rodan, Wen‐Hann Tan, Lynne M. Bird, Mark Nespeca, Joseph G. Gleeson, Yongjin Yoo, Murim Choi, Jong‐Hee Chae, Desiree Czapansky‐Beilman, Sara Chadwick Reichert, Manuela Pendziwiat, Judith S. Verhoeven, Helenius J. Schelhaas, Orrin Devinsky, Jakob Christensen, Nicola Specchio, Marina Trivisano, Yvonne G. Weber, Caroline Nava, Boris Keren, Diane Doummar, Elise Schaefer, Sarah Hopkins, Holly Dubbs, Jessica E. Shaw, Laura Pisani, Candace T. Myers, Sha Tang, Shan Tang, Deb K. Pal, John J. Millichap, Gemma L. Carvill, Kathrine L. Helbig, Oriano Mecarelli, Pasquale Striano, Ingo Helbig, Guido Rubboli, Heather C. Mefford, and Rikke S. Møller. Defining the phenotypic spectrum of slc6a1 mutations. Epilepsia, 59(2):389–402, January 2018. URL: http://dx.doi.org/10.1111/epi.13986, doi:10.1111/epi.13986. This article has 95 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1111/epi.13986)

[3. (Hirunsatit2009Twentyonebasepair) Rungnapa Hirunsatit, Elizabeth D. George, Barbara K. Lipska, Hani M. Elwafi, Lisa Sander, Carolyn M. Yrigollen, Joel Gelernter, Elena L. Grigorenko, Jaakko Lappalainen, Shrikant Mane, Angus C. Nairn, Joel E. Kleinman, and Arthur A. Simen. Twenty-one-base-pair insertion polymorphism creates an enhancer element and potentiates slc6a1 gaba transporter promoter activity. Pharmacogenetics and Genomics, 19(1):53–65, January 2009. URL: http://dx.doi.org/10.1097/fpc.0b013e328318b21a, doi:10.1097/fpc.0b013e328318b21a. This article has 24 citations and is from a peer-reviewed journal.](https://doi.org/10.1097/fpc.0b013e328318b21a)

[4. (Mattison2018SLC6A1variants) Kari A. Mattison, Kameryn M. Butler, George Andrew S. Inglis, Oshrat Dayan, Hanna Boussidan, Vikas Bhambhani, Bryan Philbrook, Cristina da Silva, John J. Alexander, Baruch I. Kanner, and Andrew Escayg. <scp>slc</scp>6a1variants identified in epilepsy patients reduce γ‐aminobutyric acid transport. Epilepsia, August 2018. URL: http://dx.doi.org/10.1111/epi.14531, doi:10.1111/epi.14531. This article has 38 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1111/epi.14531)

5. (Silva2022Haploinsufficiency) Haploinsufficiency underlies the neurodevelopmental consequences ofSLC6A1/GAT-1 variants. This article has 2 citations.

[6. (Cai2019A) Kefu Cai, Jie Wang, Jaclyn Eissman, Juexin Wang, Gerald Nwosu, Wangzhen Shen, Hui-Ci Liang, Xiao-Jing Li, Hai-Xia Zhu, Yong-Hong Yi, Jeffrey Song, Dong Xu, Eric Delpire, Wei-Ping Liao, Yi-Wu Shi, and Jing-Qiong Kang. A missense mutation in slc6a1 associated with lennox-gastaut syndrome impairs gaba transporter 1 protein trafficking and function. Experimental Neurology, 320:112973, October 2019. URL: http://dx.doi.org/10.1016/j.expneurol.2019.112973, doi:10.1016/j.expneurol.2019.112973. This article has 41 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.expneurol.2019.112973)

[7. (Goodspeed2020Current) Kimberly Goodspeed, Eduardo Pérez-Palma, Sumaiya Iqbal, Dominique Cooper, Annalisa Scimemi, Katrine M Johannesen, Arthur Stefanski, Scott Demarest, Katherine L Helbig, Jingqiong Kang, Frances C Shaffo, Brandon Prentice, Catherine A Brownstein, Byungchan Lim, Ingo Helbig, Emily De Los Reyes, Dianalee McKnight, Vincenzo Crunelli, Arthur J Campbell, Rikke S Møller, Amber Freed, and Dennis Lal. Current knowledge of slc6a1-related neurodevelopmental disorders. Brain Communications, 2020. URL: http://dx.doi.org/10.1093/braincomms/fcaa170, doi:10.1093/braincomms/fcaa170. This article has 47 citations and is from a peer-reviewed journal.](https://doi.org/10.1093/braincomms/fcaa170)

[8. (Fischer2022Molecular) Florian P. Fischer, Ameya S. Kasture, Thomas Hummel, and Sonja Sucic. Molecular and clinical repercussions of gaba transporter 1 variants gone amiss: links to epilepsy and developmental spectrum disorders. Frontiers in Molecular Biosciences, March 2022. URL: http://dx.doi.org/10.3389/fmolb.2022.834498, doi:10.3389/fmolb.2022.834498. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fmolb.2022.834498)

[9. (Pramod2013SLC6) Akula Bala Pramod, James Foster, Lucia Carvelli, and L. Keith Henry. Slc6 transporters: structure, function, regulation, disease association and therapeutics. Molecular Aspects of Medicine, 34(2–3):197–219, April 2013. URL: http://dx.doi.org/10.1016/j.mam.2012.07.002, doi:10.1016/j.mam.2012.07.002. This article has 233 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.mam.2012.07.002)

[10. (Bhatt2024Unveiling) Manan Bhatt, Erika Lazzarin, Ana Sofia Alberto-Silva, Guido Domingo, Rocco Zerlotti, Ralph Gradisch, Andre Bazzone, Harald H. Sitte, Thomas Stockner, and Elena Bossi. Unveiling the crucial role of betaine: modulation of gaba homeostasis via slc6a1 transporter (gat1). Cellular and Molecular Life Sciences, June 2024. URL: http://dx.doi.org/10.1007/s00018-024-05309-w, doi:10.1007/s00018-024-05309-w. This article has 0 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/s00018-024-05309-w)

[11. (Kalvakuntla2023Patterns) Sanjana Kalvakuntla, MinJae Lee, Wendy K. Chung, Scott Demarest, Amber Freed, Kyle J. Horning, Terry Jo Bichell, Susan T. Iannaccone, and Kimberly Goodspeed. Patterns of developmental regression and associated clinical characteristics in slc6a1-related disorder. Frontiers in Neuroscience, February 2023. URL: http://dx.doi.org/10.3389/fnins.2023.1024388, doi:10.3389/fnins.2023.1024388. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fnins.2023.1024388)

[12. (Johannesen2023The) Katrine M. Johannesen, Jimmi Nielsen, Anne Sabers, Bertrand Isidor, Anja A. Kattentidt-Mouravieva, Dominik Zieglgänsberger, Alexis R. Heidlebaugh, Kathryn F. Oetjens, Anna Abuli Vidal, Jakob Christensen, Jacob Tiller, Amber N. Freed, Rikke S. Møller, and Guido Rubboli. The phenotypic presentation of adult individuals with slc6a1-related neurodevelopmental disorders. Frontiers in Neuroscience, August 2023. URL: http://dx.doi.org/10.3389/fnins.2023.1216653, doi:10.3389/fnins.2023.1216653. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fnins.2023.1216653)

[13. (Rudnick2013The) Gary Rudnick, Reinhard Krämer, Randy D. Blakely, Dennis L. Murphy, and Francois Verrey. The slc6 transporters: perspectives on structure, functions, regulation, and models for transporter dysfunction. Pflügers Archiv - European Journal of Physiology, 466(1):25–42, December 2013. URL: http://dx.doi.org/10.1007/s00424-013-1410-1, doi:10.1007/s00424-013-1410-1. This article has 130 citations.](https://doi.org/10.1007/s00424-013-1410-1)

[14. (Carvill2015Mutations) Gemma L. Carvill, Jacinta M. McMahon, Amy Schneider, Matthew Zemel, Candace T. Myers, Julia Saykally, John Nguyen, Angela Robbiano, Federico Zara, Nicola Specchio, Oriano Mecarelli, Robert L. Smith, Richard J. Leventer, Rikke S. Møller, Marina Nikanorova, Petia Dimova, Albena Jordanova, Steven Petrou, Ingo Helbig, Pasquale Striano, Sarah Weckhuysen, Samuel F. Berkovic, Ingrid E. Scheffer, and Heather C. Mefford. Mutations in the gaba transporter slc6a1 cause epilepsy with myoclonic-atonic seizures. The American Journal of Human Genetics, 96(5):808–815, May 2015. URL: http://dx.doi.org/10.1016/j.ajhg.2015.02.016, doi:10.1016/j.ajhg.2015.02.016. This article has 163 citations.](https://doi.org/10.1016/j.ajhg.2015.02.016)